{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:23:59Z","timestamp":1792196639667,"version":"4.4.0"},"reference-count":48,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Form Res"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Obesity affects &gt;890 million adults worldwide, and traditional lifestyle interventions often lack long-term success. While glucagonlike peptide-1 receptor agonists (GLP-1RAs) have shown strong weight loss outcomes, access to specialist care is limited by cost and capacity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study evaluated the effectiveness, feasibility, acceptability, and potential cost-effectiveness of a 12-month remote GLP-1RA\u2013supported weight management program, comparing outcomes between tirzepatide and semaglutide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective analysis included 339 participants (n=278, 82% women) who completed a 12-month remote weight management program using either tirzepatide (n=209, 61.7%) or semaglutide (n=130, 38.3%) between February and June 2024. The program combined medication, app-based behavioral support, coaching from registered dietitians and nutritionists, and clinical oversight. It featured 5 phases with evidence-based behavior change techniques, monthly monitoring, and safety protocols. Primary outcomes were mean weight change and proportions achieving \u226510% and \u226515% weight loss. Secondary outcomes included behavior changes, side effects, acceptability, feasibility, and estimated cost-effectiveness compared to National Health Service care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean weight change at 12 months was \u221222.9 kg (\u201322.1% of baseline weight, SD 8%; P&lt;.001) in the tirzepatide cohort and \u221218.1 kg (\u201317.1% of baseline weight, SD 8.1%; P&lt;.001) in the semaglutide cohort. Achievement of \u226510% weight loss occurred in 95.2% (199\/209) of participants using tirzepatide and 83.1% (108\/130) of participants using semaglutide, whereas \u226515% weight loss was achieved by 83.7% (175\/209) and 56.2% (73\/130) of the participants, respectively. The proportion of inactive participants (no weekly exercise) decreased substantially in both cohorts (tirzepatide: 31\/209, 14.8% to 14\/209, 6.7%; semaglutide: 29\/130, 22.3% to 7\/130, 5.4%; P&lt;.001). Side effects decreased significantly over the 12-month period, with participants who reported no side effects increasing from 41.6% (87\/209) to 60.3% (126\/209; P&lt;.001) in the tirzepatide cohort and from 53.8% (70\/130) to 67.7% (88\/130) in the semaglutide cohort (P=.02), whereas common initial side effects, including constipation, nausea, and fatigue, showed significant reductions (P&lt;.001). Economic modeling suggested a 60% to 70% cost saving compared to specialist weight management services and a 10% to 60% cost saving compared to primary care in the National Health Service.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This real-world evaluation demonstrates that remotely delivered, GLP-1RA\u2013supported weight management programs can achieve weight loss outcomes that align closely with clinical trial results while potentially reducing health care costs by 10% to 70% compared to traditional UK services. Both the tirzepatide and semaglutide cohorts exceeded clinically significant weight loss thresholds with acceptable safety profiles and positive behavior changes. These findings support the feasibility and effectiveness of digital delivery models for expanding access to specialist obesity treatment within resource-constrained health care systems, with outcomes that compare favorably to pharmacological intervention alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2196\/81912","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T08:50:11Z","timestamp":1755593411000},"page":"e81912","source":"Crossref","is-referenced-by-count":10,"title":["Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study"],"prefix":"10.2196","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7122-6822","authenticated-orcid":false,"given":"Rebecca","family":"Richards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0749-0725","authenticated-orcid":false,"given":"William","family":"Lunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7144-7545","authenticated-orcid":false,"given":"Michael","family":"Whitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9256-6181","authenticated-orcid":false,"given":"Giulia","family":"Spaltro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9438-2219","authenticated-orcid":false,"given":"Rachel","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"ref1","unstructured":"Obesity and overweightWorld Health Organization2025572025-07-01https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(24)00316-4"},{"key":"ref3","unstructured":"Unhealthy numbers: the rising cost of obesity in the UKTony Blair Institute for Global Change202311212025-07-01https:\/\/institute.global\/insights\/public-services\/unhealthy-numbers-the-rising-cost-of-obesity-in-the-uk"},{"key":"ref4","unstructured":"BuntingTBoneJBarberJWhy reducing obesity could help to tackle the UK\u2019s productivity problemNesta2025722025-08-23https:\/\/www.nesta.org.uk\/blog\/why-reducing-obesity-could-help-to-tackle-the-uks-productivity-problem\/"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2017.08.012"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22794"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.31982"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2032183"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24945"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2206038"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2301972"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2337\/db25-1757-P"},{"key":"ref14","unstructured":"Tirzepatide for managing overweight and obesityNational Institutes for Health and Care Excellence202412232025-08-23https:\/\/www.nice.org.uk\/guidance\/ta1026"},{"key":"ref15","unstructured":"Fit for the future: 10 year health plan for England - executive summaryDepartment of Health & Social Care, United Kingdom Government20252025-08-23https:\/\/www.gov.uk\/government\/publications\/10-year-health-plan-for-england-fit-for -the-future\/fit-for-the-future-10-year-health-plan-for-england-executive-summary"},{"key":"ref16","unstructured":"Interim commissioning guidance: implementation of the NICE technology appraisal TA1026 and the NICE funding variation for tirzepatide (Mounjaro\u00ae) for the management of obesityNational Health Service England20252025-08-23https:\/\/tinyurl.com\/yvne36kr"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2196\/72577"},{"key":"ref18","unstructured":"Guide to reporting, action planning, communication and disseminationNHS Evaluation Toolkit2025-08-14https:\/\/nhsevaluation toolkit.net\/resources\/guide-to-reporting-communicating-and-acting\/"},{"key":"ref19","unstructured":"Semaglutide for managing overweight and obesityNational Institute for Health and Care Excellence20222025-07-01https:\/\/www.nice.org.uk\/guidance\/ta875\/documents\/129"},{"key":"ref20","unstructured":"Digital technologies for delivering multidisciplinary weight-management services: early value assessmentNational Institute for Health and Care Excellence20232025-07-01https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-hte10007"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2196\/53619"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2196\/15189"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/pdi.2295"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-6-42"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46091"},{"key":"ref26","unstructured":"Is my study research?National Health Service Health Research Authority2025-07-01http:\/\/www.hra-decisiontools.org.uk\/research\/"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s12961-019-0520-4"},{"key":"ref28","unstructured":"Digital technologies for delivering multidisciplinary weight-management services: early value assessmentNational Institute for Health and Care Excellence2025-07-01https:\/\/www.nice.org.uk\/guidance\/hte14\/resources\/resource-impact-template-excel -13197081133"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14725"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02026-4"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2416394"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.2525"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02597-w"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24169"},{"key":"ref36","unstructured":"Is coming off semaglutide slowly the key to preventing weight regain?European Association for the Study of Obesity20245112025-07-01https:\/\/easo.org\/is-coming-off-Semaglutide-slowly-the-key-to-preventing-weight-regain\/"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12932"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-1710"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15728"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad016"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1414268"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02996-7"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20512"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20197"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.1228"},{"key":"ref46","unstructured":"Local weight management servicesNational Health Service Cheshire and Merseyside2025-07-01https:\/\/www.cheshireandmersey side.nhs.uk\/your-health\/prescribing\/statements\/mounjaro-tirzepatide\/local-weight-management-services\/"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajcnut.2025.04.023"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.10.1069"}],"container-title":["JMIR Formative Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/formative.jmir.org\/2025\/1\/e81912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:15:49Z","timestamp":1782843349000},"score":1,"resource":{"primary":{"URL":"https:\/\/formative.jmir.org\/2025\/1\/e81912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":48,"URL":"https:\/\/doi.org\/10.2196\/81912","relation":{"has-preprint":[{"id-type":"doi","id":"10.2196\/preprints.81912","asserted-by":"object"}]},"ISSN":["2561-326X"],"issn-type":[{"value":"2561-326X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]}}}